Home

HPV na Prática Clínica

Conheça a clínica
Corpo clínico
Fale Conosco

Doenças e Disfunções
.Infertilidade
.Disfunção erétil
.Infecção urinária
.DST
.Próstata
.Rim
.Bexiga
.Testículos
.Pênis
.Cálculos urinários
.Vasectomia
.Reversão de Vasectomia

Compre o livro
HPV na Prática Clínica

Mapa de acesso ao consultório

Long-Term Clinical Studies Conclude VidaMed's TUNA System to be Safe, Effective and Durable

Five- and Six-Year Studies Presented at AUA

FREMONT, Calif.--(BW HealthWire)--June 5, 2001--VidaMed, Inc. (NASDAQ:VIDA - news), today reported five- and six-year follow-up data demonstrating the clinical efficacy of the Company's minimally invasive TUNA (Transurethral Needle Ablation) System, for the treatment of symptomatic BPH (Benign Prostatic Hyperplasia, or enlarged prostate).

Alexandre R. Zlotta, M.D., Claude C. Schulman, M.D. and Xenofon Giannakopoulos, M.D., authored the five-year study, and Dr. Zlotta presented the findings today at the American Urological Association's (AUA) Annual Meeting underway in Anaheim, Calif. In this long-term evaluation, 162 consecutive patients with symptomatic BPH were treated under local anesthesia with TUNA and were followed for five years in two different centers. The study concluded that ``TUNA is safe and effective and provides good long-term clinical improvement at 5 year follow-up. TUNA treatment stands the test of time with low and acceptable failure rates.''

Jaspal S. Virdi, M.D., Ponnambalam Chandrasekar, M.D. and Faiyaz Kapasi, M.D., Department of Urology, Princess Alexandra Hospital, Harlow, U.K. authored the six-year study, and Dr. Chandrasekar presented the findings today at the AUA Annual Meeting.

The 152-patient, single-site, prospective six-year study concluded that ``TUNA produces minimal morbidity and good patient tolerance.'' No ejaculatory dysfunction was recorded with TUNA, compared with 76% in TURP. This is often an important consideration among urologists when choosing the most suitable method for treating BPH in younger patients. Also, TUNA was found to be durable - approximately 87% of patients did not need additional treatment during the six-year trial.

``These long-term studies show the clinical efficacy and durability of the TUNA procedure and highlight important quality of life benefits for patients including the maintenance of sexual function,'' stated Randy Lindholm, chairman, president and chief executive officer of VidaMed. ``In both of these trials the TUNA 2 and TUNA 3 systems were used - state-of-the-art at the time these two trials were initiated. Today, physicians use our newest technology, the Precision Office TUNA System, with its full visual capabilities, 20-minute average treatment times and continuous monitoring of intra-prostatic temperatures.''

About the 5-Year Study

162 consecutive patients with symptomatic BPH, with a mean prostate size of 56 gms, were treated with TUNA and were followed for five years in two different centers. All patients were treated using local anesthesia only. Pre-operative and five-year follow-up evaluation included urinary peak flow, International Prostate Symptom Score (IPSS) and post-void residual urine volume.

About the 6-Year Study

From April 1994 to October 1998, 152 patients with ages ranging from 47 to 87 years (mean 67.5) and with prostatic weights ranging from 20 to 88 gms (mean 43.3) with symptomatic BPH, entered into the trial. Of the 152 patients, 76 were treated by TUNA and 76 were treated with TURP. Assessment parameters were IPSS, Quality of Life (QOL), uroflow and post-void residual.
About VidaMed

VidaMed designs, develops and markets technologically and clinically advanced cost-effective systems for the treatment of urological conditions. For investor information, call 800/363-2994 or visit the Company's Web site at www.vidamed.com.

Certain statements in this news release contain forward-looking information. Actual results may vary significantly from those anticipated in such forward-looking statements due to risks and uncertainties, including the rate of adoption of the TUNA procedure by the medical community, the impact of competitive treatments, products and pricing, the development and effectiveness of the Company's sales organization and marketing efforts, the scope and level of reimbursement coverage of the TUNA procedure by Medicare and other payors, and other risks described in the Company's reports filed from time to time with the United States Securities and Exchange Commission. The Company's actual results may differ significantly from the results anticipated by the forward-looking statements as a result of these or other factors.

Contact:

VidaMed, Inc.
Randy Lindholm/John Howe, 510/492-4900
www.vidamed.com
or
Lippert Heilshorn & Associates
310/691-7100 (investors)
Bruce Voss
Bvoss@lhai.com
Martin Halsall
Mhalsall@lhai.com